Introduction {#s1}
============

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy, characterised by fibro-fatty replacement of the right ventricular (RV) myocardium, which predisposes patients to ventricular arrhythmias (VAs), RV dysfunction and an increased risk of sudden cardiac death.[@R1] [@R2] Patients typically present in their second to fifth decade with symptoms associated with VAs.[@R3] Inheritance of ARVD/C is autosomal dominant with reduced penetrance and marked variable expressivity.[@R4] [@R5] Consistent with this, ARVD/C is equally common in men and women, although men have a somewhat worse disease course.[@R3] [@R5] Mutations, primarily in genes encoding the cardiac desmosome, can be identified in up to two-thirds of patients.[@R6]

Although ARVD/C is frequently diagnosed in childbearing-aged women,[@R6] little is known about pregnancy and ARVD/C. Published data are limited to one small case series and seven isolated case reports[@R7] describing a total of 13 pregnancies. Thus, beyond appreciation that there are likely risks associated with the hemodynamic and hormonal changes of pregnancy,[@R15] little disease-specific data exist to guide obstetric care of patients with ARVD/C. Taking advantage of a combined registry of American and Dutch patients with ARVD/C, we therefore developed a study to (1) characterise pregnancy course and outcomes in women with ARVD/C, (2) identify women at highest risk for adverse outcomes during pregnancy and (3) compare overall disease course of childbearing-aged patients who did and did not experience an ARVD/C-affected pregnancy.

Methods {#s2}
=======

Study population {#s2a}
----------------

The study population was drawn from the Johns Hopkins and Interuniversity Cardiology Institute of the Netherlands ARVD/C registries. Both prospectively follow patients with ARVD/C. As shown in [figure 1](#HEARTJNL2015308624F1){ref-type="fig"} and the online supplementary methods, for this study we included female registry enrolees who met diagnostic 2010 Task Force Criteria (TFC)[@R16] while childbearing aged (15--45 years) and for whom childbearing history (parity) was available. Twenty-six women were diagnosed with ARVD/C prior to or during at least one completed pregnancy and constituted our main study population. The remaining childbearing-aged patients with ARVD/C served as a comparison group. All registry enrolees provided informed consent. The study was approved by the respective institutional review boards.

![Ascertainment of the study population. The study population was drawn from the Johns Hopkins arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) registry (arvd.com) and the Interuniversity Cardiology Institute of the Netherlands ARVD/C registry (\*University Medical Center Utrecht, Academic Medical Center Amsterdam and University Medical Center Groningen enrolees). ^\#^Diagnosis was based on fulfilment of the 2010 Task Force Criteria.[@R16] §First-trimester fetal loss excluded.](heartjnl-2015-308624f01){#HEARTJNL2015308624F1}

ARVD/C characteristics {#s2b}
----------------------

Demographics, family history and cardiac characteristics were obtained by examination of medical records and patients' self-report as per registry protocol (see online supplementary methods). Genotype was derived from direct sequencing of the desmosomal genes and the *PLN* gene through either our research[@R17] [@R18] or commercially available testing. ARVD/C diagnosis was established when 2010 TFC were fulfilled.

Cardiac events included: (1) sustained VA and (2) onset of heart failure (HF) ≥ Class C. Sustained VA was a composite measure of spontaneous sustained ventricular tachycardia (VT), aborted sudden cardiac death or appropriate implantable cardioverter defibrillator (ICD) intervention, as described previously.[@R17] In women with multiple endpoints, the first event was considered the censoring event. Onset of Class C HF was defined based on modified guidelines of the American College of Cardiology/American Heart Association.[@R19]

Pregnancy course and outcomes {#s2c}
-----------------------------

Cardiac and obstetric course were evaluated for each ARVD/C-affected pregnancy. Maternal phenotype was assessed at evaluation preceding pregnancy with ARVD/C, during pregnancy and at last follow-up. For this assessment, *major structural RV abnormalities* were considered those meeting major structural TFC based on review of echocardiography, cardiac MRI and RV angiography. Left ventricular (LV) dysfunction was defined as LV ejection fraction below 55%. Cardiac treatment prior to and during each pregnancy was recorded. Each pregnancy was evaluated for VA and HF, which were collectively considered *major events*. New or worsening ARVD/C-related symptoms were recorded.

The primary obstetric outcome was the rate of live-born children without health issues related to pregnancy and/or delivery. For each pregnancy, gestational duration, type of delivery, birth weight, obstetric complications and perinatal health were evaluated. Maternal and child health at last clinical follow-up were also assessed.

Comparison of major events in pregnant and non-pregnant women {#s2d}
-------------------------------------------------------------

Likelihood of VA, HF, cardiac transplant and death at last follow-up was compared between women who had and had not experienced pregnancy with ARVD/C. Incidence rates of VA and HF in the pregnant versus non-pregnant state were also compared.

Statistical analysis {#s2e}
--------------------

Categorical variables were reported as frequency (%) and compared between groups by the χ^2^ or Fisher\'s exact test. Continuous variables were summarised as either mean±SD or median (IQR) and compared across groups using a t test, or Mann--Whitney U test as appropriate. Incidence rates of VA and HF were calculated as number of first VA and HF events per person-year in the pregnant versus non-pregnant state. Mid-P exact tests were used to compare incidence rates. A p value \<0.05 was considered significant. SPSS (V.22; SPSS) statistical software was used.

Results {#s3}
=======

Pregnant subjects {#s3a}
-----------------

The main study population included 26 women (21 American) who experienced at least one viable pregnancy (\>13 weeks) while affected with ARVD/C. First pregnancies began a median 1.1 years (IQR 0.5--3.8) after diagnosis. Nearly half (12/26, 46%) received genetic counselling prior to at least one pregnancy. [Table 1](#HEARTJNL2015308624TB1){ref-type="table"} shows clinical characteristics at first pregnancy.

###### 

Clinical characteristics at first pregnancy with ARVD/C

  Case   Clinically recognised ARVD/C   Proband   Mutation           Age at diagnosis (years)   Structure TFC   Tissue TFC   Depolarisation TFC   Repolarisation TFC   Arrhythmias TFC   Family history/genetics TFC
  ------ ------------------------------ --------- ------------------ -------------------------- --------------- ------------ -------------------- -------------------- ----------------- -----------------------------
  1      Yes                            Yes       *PKP2*             21                         Major           0            Minor                Major                Minor             Major
  2      Yes                            Yes       *PLN*              29                         0\*             Minor        Minor                0                    0                 Major
  3      Yes                            Yes       *PKP2*             30                         Major           Minor        Minor                Major                Minor             Major
  4      Yes                            Yes       0                  29                         0               n/a          Minor                Major                Minor             0
  5      Yes                            Yes       0                  23                         0               n/a          Minor                Major                Minor             Major
  6      Yes                            Yes       0                  28                         Major           n/a          0                    Major                Minor             0
  7      Yes                            Yes       0                  30                         Major           n/a          0                    Major                Minor             0
  8      Yes                            Yes       0                  28                         Major           n/a          Minor                Major                Minor             0
  9      Yes                            Yes       n/a                27                         0               n/a          n/a                  Major                Minor             Minor
  10     Yes                            No        *PKP2*             19                         0               n/a          Minor                Major                Minor             Major
  11     Yes                            No        *PKP2*             27                         Major           n/a          Minor                0                    Minor             Major
  12     Yes                            No        *PKP2*             32                         0               n/a          0                    Minor                Minor             Major
  13     Yes                            No        *PKP2*             28                         Major           n/a          0                    Major                Minor             Major
  14     Yes                            No        *PKP2*             21                         Major           n/a          0                    0                    Minor             Major
  15     Yes                            No        0                  32                         0               0            Minor                0                    Minor             Major
  16     Yes                            No        0                  34                         0               n/a          Minor                0                    Minor             Major
  17     Yes                            No        0                  29                         0               n/a          0                    Major                Minor             Major
  18     Yes                            No        0                  31                         0               n/a          Minor                Major                0                 Major
  19     No                             Yes       *PKP2*             22                         n/a             n/a          0                    Major                n/a               Major
  20     No                             Yes       *PKP2*             22                         0               n/a          0                    Major                0                 Major
  21     No                             Yes       *DSP* and *DSG2*   31                         n/a             n/a          Minor                Major                Minor             Major
  22     No                             No        *PKP2*             34                         0               n/a          0                    Major                n/a               Major
  23     No                             No        *PKP2*             31                         0               n/a          0                    Major                0                 Major
  24     No                             No        *PKP2*             29                         n/a             n/a          n/a                  Major                Minor             Major
  25     No                             Yes       *PKP2*             31                         Minor           n/a          0                    Minor                n/a               Major
  26     No                             No        *PKP2*             25                         Major           n/a          0                    Major                n/a               Major

\*None.

ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; n/a, not available; TFC, 2010 ARVD/C Task Force Criteria.[@R16]

Pregnancies {#s3b}
-----------

These 26 women experienced 39 singleton pregnancies progressing beyond the first trimester (range 1--4, mean age 31.3±3.6) and 6 clinically recognised first trimester losses while affected with ARVD/C ([table 2](#HEARTJNL2015308624TB2){ref-type="table"}). The majority (n=29, 74%) of viable pregnancies began after ARVD/C was clinically recognised and treated, 7 (18%) began after the patient met TFC but ARVD/C was not yet clinically recognised and 3 (8%) pregnancies were ongoing at diagnosis. Sixteen (41%) pregnancies began in the setting of major structural RV abnormalities (n=7), history of VA (n=5) or both (n=4) and were considered potentially high risk. No pregnancy began in the setting of HF. An additional 18 pregnancies (0--4 per woman)---including three miscarriages---had been completed by these women prior to ARVD/C diagnosis without any major cardiac events.

###### 

Pregnancy course and outcomes

           Characteristics at start pregnancy   Obstetrics        Treatment in pregnancy   Events during pregnancy                                                                                                                                                                                                                                                                                                                                                     
  -------- ------------------------------------ ----------------- ------------------------ ------------------------- ------------- ------------ ------------------------------------------- -------------------------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------- ------------------- ----------------------------------- --------------------------- -----
  **1**    27                                   Yes               VA+RV structure          G1P0                      Live birth    35 weeks     Vaginal                                     No                                                       2 years                                 B, dose \*2                                                                           Yes                 Palpitations/PVCs                   No                          No
  30       Yes                                                    G2P1                     Miscarriage               \<13 weeks                                                                                                                                                                                                                                                                                                                                        
  30       Yes                                  VA+RV structure   G3P1                     Live birth                Full term     Vaginal      No                                          2 months                                                 B, add flecainide in second trimester   Yes                                                                                   Palpitations/PVCs   No                                  No                          
  **2**    30                                   Yes               No                       G2P1                      Live birth    Full term    Vaginal                                     No                                                       10 years                                None                                                                                  Yes                 Fatigue, palpitations               No                          No
  40       Yes                                  No                G3P2                     Live birth                Full term     Vaginal      No                                          12 months                                                Start B in 23rd week                    Yes                                                                                   PVCs/NSVTs          No                                  No                          
  **3**    37                                   Yes               VA+RV structure          G1P0                      Live birth    Full term    Vaginal                                     Dysmaturity                                              2 years                                 B+ diuretics when needed                                                              Yes                 Dyspnoea, palpitations              No                          Yes
  **4**    32                                   Yes               VA                       G1P0                      Live birth    Full term    C-section                                   No                                                       4 years                                 Sotalol                                                                               No                  No                                  No                          No
  33       Yes                                  VA                G2P1                     Live birth                Full term     C-section    No                                          2 years                                                  Sotalol                                 Yes                                                                                   No                  No                                  No                          
  36       Yes                                                    G3P2                     Miscarriage               \<13 weeks                                                                                                                                                                                                                                                                                                                                        
  **5**    29                                   Yes               No                       G1P0                      Live birth    34 weeks     C-section                                   Preterm contractions                                     1 month                                 Sotalol+diuretics≤7 days                                                              Yes                 Mild dyspnoea                       No                          No
  **6**    28                                   Yes               RV structure             G1P0                      Live birth    Full term    Vaginal                                     Child: scalp laceration infection due to use of vacuum   5 years                                 B; change atenolol to metoprolol                                                      Yes                 Palpitations                        Third week: ICD discharge   No
  **7**    33                                   Yes               VA+RV structure          G1P0                      Live birth    Full term    C-section                                   No                                                       9 months                                B                                                                                     Yes                 No                                  No                          No
  **8**    28                                   Yes               VA                       G1P0                      Live birth    Full term    Vaginal                                     No                                                       9 months                                B                                                                                     Yes                 No                                  No                          No
  **9**    29                                   Yes                                        G1P0                      Miscarriage   \<13 weeks                                                                                                                                                                                                                                                                                                                          
  30       Yes                                  No                G2P0                     Live birth                Full term     Vaginal      No                                          4 years                                                  B                                       Yes                                                                                   No                  No                                  No                          
  31       Yes                                  No                G3P1                     Live birth                Full term     Vaginal      Temporary intrauterine growth restriction   3 years                                                  Stop B→VA→restart B                     Yes                                                                                   No                  18th week: antitachycardia pacing   No                          
  33       Yes                                  VA                G4P2                     Live birth                Full term     Vaginal                                                  23 months                                                B                                       Yes                                                                                   No                  No                                  No                          
  34       Yes                                  VA                G5P3                     Live birth                Full term     Vaginal      Meconium-stained amniotic fluid             3 months                                                 B                                       Yes                                                                                   No                  No                                  No                          
  **10**   24                                   Yes               No                       G1P0                      Live birth    Full term    Vaginal                                     No                                                       6 years                                 None (stop B in 4th--8th week)                                                        Yes                 No                                  No                          No
  26       Yes                                  No                G2P1                     Live birth                Full term     Vaginal      Preterm contractions                        5 years                                                  None (stop B in 4th--8th week)          Yes                                                                                   No                  No                                  No                          
  28       Yes                                  No                G3P2                     Live birth                Full term     Vaginal      No                                          3 years                                                  None (stop B in 4th--8th week)          Yes                                                                                   No                  No                                  No                          
  **11**   31                                   Yes               RV structure             G1P0                      Live birth    Full term    C-section                                   No                                                       5 years                                 B; stop valsartan; 22nd week: + diuretics; 32nd week: + digoxin, increase diuretics   Yes                 Dyspnoea, oedema, fatigue           No                          Yes
  **12**   33                                   Yes               No                       G3P1                      Live birth    Full term    Vaginal                                     No                                                       2 years                                 None                                                                                  Yes                 No                                  No                          No
  **13**   30                                   Yes               RV structure             G1P0                      Live birth    Full term    C-section                                   Child: hypoglycaemia in macrosomia                       16 years                                None                                                                                  Yes                 No                                  No                          No
  34       Yes                                                    G2P1                     Miscarriage               \<13 weeks                                                                                                                                                                                                                                                    No                                                      No                          
  35       Yes                                  RV structure      G3P1                     Live birth                Full term     C-section    No                                          11 years                                                 None                                    Yes                                                                                   No                  No                                  No                          
  **14**   25                                   Yes               RV structure             G1P0                      Live birth    Full term    Vaginal                                     No                                                       3 years                                 None                                                                                  Yes                 No                                  No                          No
  27       Yes                                                    G2P1                     Miscarriage               \<13 weeks                                                                                                                                                                                                                                                    No                                                      No                          
  28       Yes                                  RV structure      G3P1                     Live birth                Full term     Vaginal      No                                          Newborn                                                  None                                    Yes                                                                                   No                  No                                  No                          
  **15**   32                                   Yes               No                       G5P2                      Live birth    Full term    Vaginal                                     No                                                       3 years                                 None                                                                                  No                  No                                  No                          No
  **16**   34                                   Yes               No                       G2P1                      Live birth    Full term    Vaginal                                     No                                                       18 months                               None                                                                                  No                  No                                  No                          No
  **17**   32                                   Yes               No                       G3P2                      Live birth    Full term    Vaginal                                     No                                                       2 years                                 B                                                                                     Yes                 Palpitations/PVCs                   No                          No
  **18**   32                                   Yes               No                       G2P1                      Live birth    Full term    Vaginal                                     No                                                       4 months                                None                                                                                  No                  No                                  No                          No
  **19**   31                                   No                No                       G1P0                      Live birth    Full term    C-section                                   No                                                       9 years                                 None                                                                                  No                  No                                  No                          No
  33       No                                   No                G2P1                     Live birth                Full term     C-section    No                                          7 years                                                  Start B since VA                        Yes                                                                                   Palpitations        12 weeks: VT                        No                          
  **20**   23                                   No                No                       G2P1                      Live birth    Full term    Vaginal                                     No                                                       9 years                                 None                                                                                  No                  No                                  No                          No
  **21**   32                                   No                No                       G2P1                      Live birth    Full term    C-section                                   No                                                       18 months                               Stop B in 4th week →VA→start sotalol                                                  Yes                 PVCs                                6th week: VT+short VF       No
  **22**   34                                   No                No                       G3P2                      Live birth    Full term    Vaginal                                     No                                                       6 years                                 None                                                                                  No                  No                                  No                          No
  **23**   34                                   No                No                       G3P2                      Live birth    Full term    C-section                                   No                                                       6 years                                 None                                                                                  No                  No                                  No                          No
  **24**   29                                   No                No                       G2P1                      Live birth    Full term    Vaginal                                     No                                                       22 years                                None                                                                                  No                  Palpitations/PVCs                   No                          No
  31       No                                                     G3P2                     Miscarriage               \<13 weeks                                                                                                                                                                                                                                                                                                                                        
  31       No                                   RV structure      G4P2                     Live birth                Full term     Vaginal      No                                          19 years                                                 None                                    No                                                                                    Fatigue             No                                  No                          
  **25**   31                                   No                No                       G1P0                      Live birth    Full term    Vaginal                                     No                                                       3 years                                 Start B since VA                                                                      Yes                 No                                  6 weeks: VT                 No
  32       Yes                                  No                G2P1                     Live birth                Full term     Vaginal      No                                          2 years                                                  B, dose \*2 when needed                 Yes                                                                                   Palpitations        No                                  No                          
  **26**   25                                   No                No                       G1P0                      Live birth    Full term    Vaginal                                     Meconium stained amniotic fluid                          5 years                                 None                                                                                  No                  No                                  No                          No

\*Gravidity--parity: gravidity refers to the number of times a subject has been pregnant including the current pregnancy, parity to the number of times a subject has given birth to a fetus with a gestational age of 24 weeks or more.

ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; B, β blocker; C-section, caesarean section; GP, gravidity--parity; HF, heart failure ≥ Class C[@R19]; ICD, implantable cardioverter defibrillator; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex; RV structure, structural abnormalities of the right ventricle that met major structural 2010 Task Force Criteria[@R16]; VA, sustained ventricular arrhythmia or appropriate ICD therapy for a ventricular arrhythmia; VF, ventricular fibrillation; VT, sustained ventricular tachycardia.

Cardiac management and outcomes of ARVD/C pregnancies {#s3c}
-----------------------------------------------------

Cardiac and obstetric course and medical management of each ARVD/C affected pregnancy are described in detail in [table 2](#HEARTJNL2015308624TB2){ref-type="table"}. Treatment during pregnancy included β blockers (n=16), antiarrhythmics (n=6), diuretics (n=3) and ICDs (n=28). ICDs were implanted during three pregnancies.

As summarised in [figure 2](#HEARTJNL2015308624F2){ref-type="fig"}, most pregnancies (n=32, 82%) were completed without major cardiac events (VA or HF). Among these pregnancies, nine involved new or worsening palpitations/premature ventricular complexes (n=7) and/or fatigue/dyspnoea (n=3). These symptoms were successfully treated via starting/increasing β blockers (n=3), adding flecainide (n=1) or short-term use of diuretics (n=1). In four symptomatic pregnancies (case 2---G2P1, case 17, case 24---G2P1 and G4P2), no medication adjustments were required.

![Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) pregnancies affected by major cardiac events stratified by prepregnancy cardiac history. A. Most pregnancies were completed without major cardiac events. Heart failure ≥ Class C occurred exclusively in high-risk pregnancies begun with major structural right ventricular (RV) abnormalities (by 2010 Task Force Criteria[@R16]). Ventricular arrhythmias did not recur during pregnancy. VA, sustained ventricular arrhythmia or appropriate implantable cardioverter defibrillator therapy for a ventricular arrhythmia. B. Worsening cardiac symptoms occurred in the absence of major cardiac events in 9 pregnancies.](heartjnl-2015-308624f02){#HEARTJNL2015308624F2}

Seven pregnancies were complicated by VA (n=5) or HF (n=2). As shown in [table 3](#HEARTJNL2015308624TB3){ref-type="table"}, the likelihood of a major cardiac event was not significantly increased in pregnancies begun in women with a prior history of VA and/or major structural RV abnormalities.

###### 

Association of major cardiac events during pregnancy with demographic, clinical and obstetric characteristics

                                                   Overall (n=39)   Major cardiac events (n=7)   No major events (n=32)   p Value major event vs none   
  ------------------------------------------------ ---------------- ---------------------------- ------------------------ ----------------------------- -------
  Maternal characteristics                                                                                                                              
   Age (at conception; mean, years)                31.3±3.6         31.7±1.9                     34.4±4.7                 31.0±3.7                      0.34
   Nationality (% American)                        31 (79)          5 (100)                      1 (50)                   25 (78)                       1.0
   Primigravida (%)                                14 (36)          2 (40)                       2 (100)                  10 (31)                       0.23
   Proband (%)                                     21 (54)          5 (100)                      1 (50)                   15 (47)                       0.10
   Mutation carrier (%)                            25 (64)          3 (60)                       2 (100)                  20 (63)                       0.65
  ARVD/C history prepregnancy                                                                                                                           
   Recognised disease (%)                          29 (74)          2 (40)                       2 (100)                  25 (78)                       0.34
   ICD implanted (%)                               25 (64)          2 (40)                       2 (100)                  21 (66)                       0.69
  Cardiac characteristics prepregnancy                                                                                                                  
   Sustained VT/ICD shock (%, VA)                  9 (23)           0 (0)                        1 (50)                   8 (25)                        1.0
   Major structural RV disease by 2010 TFC\* (%)   11/37 (30)       1 (20)                       2 (100)                  8/30 (27)\*                   0.40
   LV ejection fraction \<55% (%)                  2 (5)            0 (0)                        1 (50)                   1 (3)                         0.33
   Heart failure ≥ Class C (%, HF)                 0 (0)            0 (0)                        0 (0)                    0(0)                          1.0
  Obstetric outcomes                                                                                                                                    
   Liveborn (%)                                    39 (100)         5 (100)                      2 (100)                  32 (100)                      1.0
   Delivery (% vaginal)                            28 (72)          3 (60)                       1 (50)                   24 (75)                       0.38
   Birth weight (mean, kg)†                        3.4±0.6          3.0±0.4                      2.9±1.3                  3.5±0.6†                      0.047
   Full-term delivery (% ≥37 weeks)                37 (95)          5 (100)                      2 (100)                  30 (94)                       1.0

\*RV structure prepregnancy was unavailable in two cases.

†Birth weight was unavailable for one full-term healthy infant.

ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; HF, heart failure ≥ Class C[@R19]; ICD, implantable cardioverter defibrillator; LV, left ventricular; RV, right ventricular; TFC, 2010 Task Force Criteria[@R16]; VA, sustained ventricular arrhythmia or appropriate ICD therapy; VT, ventricular tachycardia.

### Ventricular arrhythmias {#s3c1}

A single episode of VA complicated five pregnancies of five women without a prior history of sustained VAs. Interruption of β blockade was associated with two of these events.

Two VAs were terminated by appropriate ICD interventions. The first was an ICD discharge in the third week of a primigravida (case 6) who had increasingly frequent non-sustained VT prepregnancy. The second was a second trimester episode of anti-tachycardia pacing following a trial β blocker interruption. With restarted β blocker therapy this woman (case 9) completed this pregnancy without further VA and had three other uneventful pregnancies maintained on β blockers.

Three women experienced episodes of sustained VT prior to appropriate clinical recognition of their disease. Case 19 had a haemodynamically stable VT in week 12 of her second pregnancy. She was externally cardioverted, began metoprolol and received an ICD 3 days later. Case 21 had a haemodynamically unstable VT in the sixth week of her second pregnancy---2 weeks after discontinuing metoprolol. VT was terminated by cardioversion, sotalol 240 mg daily started and an ICD placed in week 22. Finally, a sustained VT in the sixth gestational week was the initial clinical presentation of a primigravida (case 25) subsequently treated with metoprolol 75 mg daily and ICD placement.

Overall, VA occurred more frequently in pregnancies of probands (5/21, 24%) than family members (0/18, 0%; p=0.05). Surprisingly, probands with no prepregnancy history of VA were most at risk (5/12 (42%) vs 0/9 (0%) probands with prepregnancy VA; p=0.045).

### Heart failure {#s3c2}

Two pregnancies of primagravidae were complicated by the onset of HF. Case 3 had a prepregnancy history of VA, major structural RV abnormalities and mild tricuspid insufficiency. She presented with dyspnoea and palpitations and was diagnosed with RV-predominant HF with severe tricuspid insufficiency in the fifth gestational month. She was successfully treated on an outpatient basis with diuretics and had an uncomplicated full-term vaginal delivery. During 2 years of follow-up, she was stable with partially improved tricuspid valve function.

Case 11 had overt biventricular disease prepregnancy (LV ejection fraction 30%--35%). Following recognition of pregnancy, she discontinued valsartan and was managed on metoprolol 25 mg daily. She developed dyspnoea, mild lower extremity oedema and increased fatigue in the fifth month and was diagnosed with biventricular HF with a decreasing LV ejection fraction (25%--30%) and mild-to-moderate pulmonary hypertension. Outpatient management was achieved with diuretics and digoxin. An uncomplicated caesarean section, indicated due to hemodynamic concerns, was performed at 39 weeks. With restart of valsartan and continued use of diuretics and digoxin, she is stable 5 years postpartum with unchanged LV function.

While HF was rare, it occurred in one of two pregnancies begun in the setting of LV dysfunction. In contrast, 9/10 (90%) pregnancies begun with major structural disease restricted to the RV were without HF.

Obstetric outcomes {#s3d}
------------------

All viable pregnancies progressing beyond the first trimester resulted in live-born children. Thirty-seven (95%) were delivered full term, and the other two preterm at 34 and 35 weeks. All were delivered in hospital. A total of 11 caesarean sections (28%) were performed: one exclusively for ARVD/C-related reasons (HF), the remainder for primarily obstetric indications. Minor obstetric complications ([table 2](#HEARTJNL2015308624TB2){ref-type="table"}) were noted in seven pregnancies (18%); no major obstetric complications occurred. As shown in [table 3](#HEARTJNL2015308624TB3){ref-type="table"}, birth weight was significantly lower (but normal) in pregnancies complicated by a major event (3.0±0.63 kg vs 3.5±0.57 kg no major events; p=0.047). This may be partly attributable to β blockade as birth weight was significantly lower in women taking β blockers beyond the eighth week (n=16) (3.1±0.48 kg vs 3.7±0.57 kg; p=0.002). There were no other differences in obstetric outcomes associated with major cardiac events during pregnancy. All children were alive and well at last follow-up at a median age of 3.4 years (IQR 1.6--6.8).

Association of ARVD/C course with pregnancy history {#s3e}
---------------------------------------------------

We explored whether experiencing pregnancy while affected with ARVD/C was associated with long-term disease course by comparing women who had pregnancies with ARVD/C with the remainder of our population of female childbearing-aged patients. As shown in [table 4](#HEARTJNL2015308624TB4){ref-type="table"}, at ARVD/C diagnosis there were no significant differences in clinical or demographic characteristics between women who later became pregnant and those who did not. After a mean 6.5±5.6 years of follow-up, there were likewise no significant differences in likelihood of having experienced a sustained VA or HF and no difference in likelihood of major RV structural dysfunction. All patients with ARVD/C who became pregnant were without cardiac mortality or transplant at last follow-up with none lost to follow-up. One woman died 1 year after her last delivery from breast cancer.

###### 

Association of long-term clinical course of childbearing-aged patients with ARVD/C with pregnancy history

                                                                       All (n=143)   Pregnancy with ARVD/C\* (n=26)   No pregnancies while diagnosed (n=117)   p Value
  -------------------------------------------------------------------- ------------- -------------------------------- ---------------------------------------- ---------
  Demographic characteristics                                                                                                                                  
   Proband (%)                                                         83 (58)       13 (50)                          70 (60)                                  0.36
   Mutation carrier (%)                                                95 (67)       16 (64)                          79 (68)                                  0.69
   European ancestry                                                   138 (96)      26 (100)                         112 (96)                                 0.59
  Clinical characteristics at diagnosis                                                                                                                        
   Age (median, IQR)                                                   30 (21--39)   28 (25--32)                      31 (21--41)                              0.14
   Sustained VT/VF (% VA)                                              50 (35)       6 (23)                           44 (38)                                  0.16
   Heart failure ≥ Class C (%)                                         2 (1.7)       0 (0)                            2 (1.4)                                  1.0
   Major RV structural abnormalities by Task  Force Criteria (n=132)   54/132 (41)   8/25 (32)                        46/107 (43)                              0.31
  Cardiac outcomes at last follow-up                                                                                                                           
   Sustained VT/ICD shock (% VA)                                       73 (51)       12 (46)                          61 (52)                                  0.58
   Heart failure ≥ Class C (%)                                         16 (11)       2 (8)                            14 (12)                                  0.73
   Major RV structural abnormalities (by TFC)                          68 (48)       10 (39)                          58 (50)                                  0.31
   Transplant                                                          3 (2.1)       0 (0)                            3 (2.6)                                  1.0
   Death                                                               4 (3)         1 (4)                            3 (3)                                    0.56
  Follow-up duration (mean years from diagnosis)                       6.5±5.6       8.2±5.3                          6.1±5.6                                  0.08

\*Pregnancy proceeding beyond the first trimester. ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; ICD, implantable cardioverter defibrillator; RV, right ventricular; TFC, 2010 ARVD/C Task Force Criteria[@R16]; VA, sustained ventricular arrhythmia or appropriate ICD therapy for a ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.

Incidence rate of VAs and HF in pregnant and non-pregnant women {#s3f}
---------------------------------------------------------------

Finally, to test whether incidence of VA and HF was more likely during pregnancy, we compared incidence rates of both in the pregnant and non-pregnant state. Among female patients with ARVD/C aged 15--45 years, the incidence rate of VA was 0.138 (CI 0.10 to 0.18) per non-pregnant person-year versus 0.274 (CI 0.10 to 0.61) per pregnant person-year (p=0.17). For HF, the observed incidence rates were 0.020 per person-year (CI 0.012 to 0.034) in non-pregnant versus 0.070 per person-year (CI 0.012 to 0.23) in pregnant state (p=0.16).

Discussion {#s4}
==========

Main findings {#s4a}
-------------

We investigated cardiac and obstetric outcomes of pregnant patients with ARVD/C ascertained from two large ARVD/C registries. Our study has four main findings. First, the majority of pregnancies were without major cardiac events. Sustained VA complicated 13% of pregnancies and HF 5%. Second, pregnancies resulted in live-born infants without major obstetric concerns and all children healthy at last follow-up. Third, at last follow-up, all pregnant patients with ARVD/C were without cardiac mortality or transplant and did not differ from other childbearing-aged patients with ARVD/C. Finally, the likelihood of experiencing a first sustained VA or developing HF was not significantly increased during pregnancy.

Prior reports of pregnancy in patients with ARVD/C {#s4b}
--------------------------------------------------

Only 13 pregnancies in patients with ARVD/C have been described in the literature, in contrast to far more robust populations for other inherited cardiomyopathies and arrhythmia syndromes.[@R20] Bauce *et al*[@R7] reported six Italian patients with mild-to-moderate ARVD/C who tolerated pregnancy well. Two authors described cases diagnosed during pregnancy who following ICD implantation and initiation of β blocker therapy delivered healthy infants.[@R8] [@R9] Güdücu *et al*[@R10] describe an established ARVD/C patient with worsening symptoms during her second pregnancy due to β blocker interruption. In contrast, two primigravidae had full-term uncomplicated pregnancies while maintained on β blockers.[@R11] [@R12] Finally, Iriyama *et al*[@R13] and Anouar *et al*[@R14] each report an uneventful pregnancy with caesarean delivery in an established patient. The results of our study confirm and significantly extend these findings as we assessed cardiac and obstetric outcomes of sixfold more pregnancies than the largest prior report.[@R7]

Most ARVD/C pregnancies were without major cardiac events {#s4c}
---------------------------------------------------------

We found most pregnancies, including those begun in the setting of major structural RV abnormalities and/or a history of sustained VAs, were free from major cardiac events. Isolated episodes of VA complicated five pregnancies of probands without prepregnancy VA history. The occurrence of four of these VAs in the first trimester might be related to an arrhythmogenic effect of hormonal changes at this time.[@R21] [@R22] Altogether, these results suggest fairly good arrhythmic outcomes when ARVD/C is well established and treatment adequate, particularly given the typical arrhythmic course of ARVD/C.[@R6] HF developed in the second trimester of two women with pre-existing significant structural disease as hemodynamic load increased. Of note, HF did not develop in 90% of pregnancies begun with isolated RV abnormalities.

The reason for this favourable outcome is uncertain. In patients with ARVD/C, increased hemodynamic stress associated with exercise promotes arrhythmias and also negatively modifies cardiac structure.[@R23] In contrast to exercise, the relatively shorter term and gradually developing nature of hemodynamic load during pregnancy might limit this process. In animal models, the myocardial response to volume- or pressure-induced stress is different in male and female hearts, with preserved ejection fraction and less fibrosis in female models. In addition, the interrelationship between oestrogen and testosterone may contribute to sex differences in disease manifestation.[@R24] Similar mechanisms may also be protective in pregnancy.

Favourable obstetric outcomes {#s4d}
-----------------------------

The obstetric course of patients with ARVD/C was largely unremarkable. All pregnancies resulted in healthy children without major obstetric complications. Both prematurity (6.5% of American subjects) and birth weights were normal,[@R25] [@R26] although women taking β blockers or experiencing major events during pregnancy had children with a significantly lower birth weight. First trimester losses represented a normal rate of 13% of clinically recognised pregnancies.[@R27] Of 11 caesarean sections, only one was exclusively ARVD/C indicated (HF). The 28% caesarean-section rate was unremarkable, given the population rates of 33% in the USA and 17% in the Netherlands.[@R28]

No differences in long-term ARVD/C course and incidence of cardiac events {#s4e}
-------------------------------------------------------------------------

Among women of childbearing age with ARVD/C, the incidence rate of VA and HF was not significantly elevated during pregnancy. All pregnant patients with ARVD/C were without cardiac mortality or transplant at last follow-up. Furthermore, there was no difference in likelihood of sustained VA or HF at last follow-up between these mothers and women who had not experienced pregnancy with ARVD/C. This suggests that pregnancy does not lead to a precipitous decline in most women. Some caution while interpreting these data is warranted as pregnancy is, of course, not randomly selected.

Implications for clinical care {#s4f}
------------------------------

Our results suggest most patients with ARVD/C can be managed successfully through pregnancy and highlight several management considerations. Preconception arrhythmia management should be optimised using drugs with low fetal toxicity. ICD implantation, if indicated based on prepregnancy risk stratification,[@R6] [@R17] should be performed prior to pregnancy. Preconception assessment of biventricular structure and function is helpful since HF is more likely in those with structural abnormalities. LV dysfunction is associated with poor pregnancy outcomes in women with dilated cardiomyopathy[@R20] and appears likely to be so for patients with ARVD/C as well. Genetic counselling to discuss the heritable nature of ARVD/C should be offered. Following recognition of pregnancy, discontinuation of medication with low fetal risk (eg, β blockers) is not advised. Vaginal delivery with cardiac monitoring is reasonable in many cases. For uneventful pregnancies, a 3-month postpartum visit followed by usual cardiac care is recommended as pregnancy is not expected to worsen long-term disease course.

Study limitations {#s4g}
-----------------

Data were obtained from two registries; as such, management decisions were at the discretion of the treating physician and hence vary between pregnancies and between subjects. In particular, variability in evaluation of cardiac structure and function precluded definitive analysis of possible structural progression during pregnancy. While ARVD/C management is similar in America and the Netherlands,[@R5] [@R6] obstetric care differs substantially which may have influenced outcomes. However, while Dutch women have high rates of care by midwives, home-births, drug-free deliveries and relatively low caesarean section rates,[@R28] the Dutch patients with ARVD/C had medically managed pregnancies with hospital deliveries.

Our study included no women with HF diagnosed prepregnancy, a population likely at very high risk. Ascertainment of subjects through a registry of living patients also creates a selection bias that may mask catastrophic pregnancy outcomes. With regard to comparison of long-term outcomes in the overall population, women obviously self-selected whether to become pregnant and hence may differ in some systematic way beyond the data shown in [table 4](#HEARTJNL2015308624TB4){ref-type="table"}. In particular, a subset of women may have been advised against pregnancy, but data on medical advice given regarding childbearing are unavailable.

Conclusions {#s5}
===========

We found most pregnancies in women with ARVD/C are tolerated well. Even most patients with a prior history of sustained VAs and isolated RV structural disease had favourable outcomes. However, β-blocker therapy was associated with lower birth weight and patients with pre-existing overt biventricular disease are likely at significant risk for developing HF as pregnancy progresses. Key messagesWhat is already known on this subject?Only 13 pregnancies in women with arrhythmogenic right ventricular dysplasia/cardiomyopathy have been described in the literature in one small case series and seven case reports.What might this study add?We assess cardiac and obstetric outcomes of 39 pregnancies, triple the number previously reported. We also compare incidence of ventricular arrhythmias and heart failure in the pregnant and non-pregnant state, and long-term outcomes of childbearing-aged patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) who became pregnant with those who did not.How might this impact on clinical practice?This study significantly enhances the evidence base for patients with ARVD/C considering pregnancy and their physicians. These results suggest that most pregnancies of patients with ARVD/C are tolerated well. However, 13% of pregnancies were complicated by sustained ventricular arrhythmias and 5% by onset of heart failure.
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